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An international expanded access program was initiated to provide access to treatment with
pemetrexed prior registration and reimbursement for malignant mesothelioma (MM).
Chemonaı¨ve and pretreated patients with inoperable MM of the pleura or peritoneum were
eligible. This report describes the results obtained in German centers. Investigators could
choose between three treatments: Pemetrexed 500 mg/m2 alone (P) or in combination with
cisplatin 75 mg/m2 (PC) or carboplatin AUC 5 (PCb).
From November 2002 to June 2004, a total of 567 patients (554 with pleural MM; 41% pre-
treated) were included. Of 548 evaluable patients with pleural MM, 191 received P, 137 PC
and 220 PCb. Patients in the P group were more often pretreated (70%) and had worse perfor-
mance status compared with the other groups. In the P, PC, and PCb groups overall response102 601 188.
eb.de (M. Reck).
9 Elsevier Ltd. All rights reserved.
Pemetrexed with or without platinum for mesothelioma 143rate (ORR) was 16%, 24% and 18%, median time to progression (TTP) was 5.5, 8.2, and 6.9
months, and median overall survival (OS) was 8.7, 11.3 and 9.7 months respectively. Efficacy
outcomes were better for chemonaı¨ve than for pretreated patients, and P was less hemato-
toxic than PC or PCb.
Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe
and active as first and second-line therapy.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Malignant mesothelioma (MM) is an aggressive malignancy
arising from the serosal lining of various body cavities.1e3
Most MMs are pleural mesotheliomas; peritoneal mesothe-
lioma represents approximately 15% to 25% of all meso-
theliomas,1,3 and MMs of the pericardium or tunica vaginalis
testis are extremely rare.4,5 In the majority of cases, the
etiology of MM is closely related to chronic asbestos expo-
sure.6 As a result of the long latency period between first
exposure to asbestos and the onset of MM, often exceeding
40 years, the incidence of MM is still increasing worldwide,
whereas the rising mortality rate will soon level off in
Western Europe.7 In 2004, a total of 780 newly diagnosed
cases were reported to the German Mesothelioma Registry,8
but the true incidence of MM in Germany is probably higher.
The prognosis of MM remains dismal, with a median
survival of 9e12 months.9 Until recently, the results
reported with chemotherapy were disappointing, and no
particular regimen was generally accepted as treatment
standard.9
Pemetrexed is a novel multitargeted antifolate that
inhibits thymidylate synthase, dihydrofolate reductase
(DHFR) and glycinamide ribonucleotide formyl transferase
(GARFT) enzymes involved in purine and pyrimidine
synthesis. After the efficacy and safety of pemetrexed
alone and in combination with cisplatin in the treatment of
mesothelioma had been demonstrated,10,11 a randomized
phase III trial was performed in 456 patients with malignant
pleural mesothelioma to compare single agent cisplatin
with pemetrexed plus cisplatin.12 Patients treated with the
combination had a significantly improved response rate
(41% vs. 17%), median time to progression (5.7 vs. 3.9
months) and median overall survival (12.1 vs. 9.3 months)
compared with the control group. Based on these results,
the pemetrexed plus ciplatin combination was approved by
the Food and Drug Administration and the European Medi-
cines Agency (EMEA) for the treatment of inoperable
malignant pleural mesothelioma.
Although the treatment results obtained with pemetrexed
plus cisplatin are promising, many patients may not be suit-
able for cisplatin-containing combinations due to comorbid-
ities, poor performance status or advanced age. For these
patients, carboplatin-containing combinations or single agent
pemetrexed may be attractive treatment options.
Access to pemetrexed was provided in an international
Expanded Access Program (EAP) performed in 13 European
countries, including 3256 patients with pleural (nZ 3124)
or peritoneal (nZ 113) mesothelioma.13,14 Pemetrexed was
administered as a single agent or in combination with
cisplatin or carboplatin. Here we report the results from
the subgroup of German patients, representing 17.4% of the
total patient population of the European EAP.Patients and methods
Patient selection
Patients aged 18 years or more were eligible if they had
histologically proven malignant mesothelioma with or
without prior treatment and were not candidates for
curative surgery. Patients previously treated with peme-
trexed were only included if they had responded or
received a clinical benefit from treatment. If patients had
undergone pleurodesis, a minimum delay of 2 weeks
before starting study treatment was recommended to
permit resolution of an acute inflammatory response.
Patients with adequately treated and stable brain metas-
tases could be enrolled if they did not require cortico-
steroid therapy. Patients were also required to have
adequate bone marrow, hepatic, and renal function
defined as absolute neutrophil count 1.5  109/L,
platelets 100  109/L, hemoglobin 9 g/dL;
bilirubin 1.5 times the upper limit of normal (ULN),
alkaline phosphatase (AP), aspartate transaminase (AST)
and alanine transaminase (ALT) 3.0  ULN (AP, AST, and
ALT 5  ULN was acceptable in the case of liver
involvement); calculated creatinine clearance (CrCl)
45 mL/min based on the standard Cockcroft and Gault
formula or on measured glomerular filtration rate (GFR)
using the appropriate radiolabeled method (51Cr-EDTA or
Tc99 m-DTPA). Karnofsky performance status had to be 70
or higher at study entry and after any palliative measures
including pleural drainage for pleural effusion were
administered. All study candidates were required to
provide written informed consent. The study was per-
formed in accordance with the Declaration of Helsinki and
the principles of Good Clinical Practice.Study design and treatment
The EAP program was a non-randomized, open-label study of
pemetrexed in patients with malignant mesothelioma.
Patient access to pemetrexed (Alimta, Lilly Deutschland
GmbH, Bad Homburg, Germany) was provided for this indi-
cation under the study protocol prior to and during regula-
tory review for commercial release. Investigators had three
treatment options: pemetrexed 500 mg/m2 plus cisplatin
75 mg/m2 (PC), single agent pemetrexed 500 mg/m2 (P), or
pemetrexed 500 mg/m2 plus carboplatin AUC 5 (PCb).
Treatment was administered intravenously on day 1 of a 21-
day cycle that was repeated until disease progression,
inacceptable toxicity or study discontinuation due to patient
or investigator decision. The choice of treatment for the
individual patient was at the investigator’s discretion,
considering the patient’s clinical status, prior treatment,
144 M. Reck et al.and the therapeutic goal. For patients with poor perfor-
mance status and/or organ dysfunction the use of single
agent pemetrexed was encouraged.
Supplementation with folic acid and vitamin B12 was
given routinely with each treatment regimen, starting
about 1e2 weeks prior to the first dose of pemetrexed, and
continued throughout treatment. Oral folic acid was given
at daily doses of 350e600 mg or equivalent, and 1000-mg
doses of vitamin B12 were injected intramuscularly
approximately every 9 weeks. Oral dexamethasone 4 mg or
another corticosteroid at an equivalent dose was given
twice daily the day before, the day of administration, and
the day after each dose of pemetrexed. Antiemetic
prophylaxis was recommended.
Data collection
Assessments included hematologic toxicity graded accord-
ing to National Cancer Institute Common Toxicity Criteria
(NCI CTC), Version 2.0,15 tumor response (preferably
according to RECIST criteria, but Southwest Oncology Group
[SWOG] criteria and World Health Organization [WHO]
criteria were also allowed),16 time to progression (TTP),
and overall survival (OS). Response was evaluated at study
discontinuation, but if a patient had additional tumor
response assessments at interim or follow-up visits the best
response was chosen for analysis. Safety follow-up was 30
days after completion of treatment or until resolution of
any treatment-emergent adverse effect. No formal follow-
up for treatment efficacy or death was required.
Statistical analysis
Data evaluations were performed in the safety population
and among evaluable patients, as appropriate, and sepa-
rately for patients with pleural and peritoneal mesothe-
lioma, and for chemonaı¨ve and previously treated patients.Table 1 Baseline characteristics of patients with pleural me
treatment group.
Chemonaı¨ve
(nZ 307)
Previously treated
(nZ 213)
Total (
PC* (n
Age, years
Median (range) 65 (35e85) 63 (38e81) 63
Male gender, n (%) 263 (86) 179 (84) 124
Caucasian, n (%) 306 (100) 213 (100) 136
Karnofsky PS, n (%)
90e100 193 (63) 110 (52) 94
70e80 110 (36) 99 (46) 41
50e60 0 (0) 1 (<1) 0
Unknown 4 (1) 3 (1) 2
Previously treated, n (%) e e 24/127
Histology
Sarcomatoid 24 (8) 12 (6) 9
Epithelial 206 (67) 155 (73) 91
Mixed cell 34 (11) 19 (9) 19
Other 43 (14) 27 (13) 18
*PC, pemetrexedþ cisplatin; P, pemetrexed; PCb, pemetrexedþ carbThe intention-to- treat population included all enrolled
patients with malignant mesothelioma, and the safety
population included all patients who received at least one
dose of the study treatment. For the safety analysis,
descriptive methods were used without any formal statis-
tical testing. Overall survival and time to progression were
estimated using the Kaplan-Meier method and compared
between treatment groups using a log-rank test. Response
rates, median survival, median time to progression, and 1-
year survival rates are shown with 95% confidence intervals
(95% CI). If there was no follow-up visit or if patients dis-
continued before disease progression or death occurred,
these patients were censored. For all data analyses SAS
software, Version 8.2, was used.
Results
From November 2002 to June 2004, a total of 567 eligible
patients, including 554 with pleural and 13 with peritoneal
mesothelioma, were enrolled to the EAP from 14 institu-
tions in Germany. All but 6 patients were assigned to one of
the study treatments and received at least one dose of
study medication. Thus, the safety population comprised
561 patients. The baseline characteristics of the 548
patients with pleural mesothelioma included in the safety
population are shown in Table 1; all characteristics were
similar to those of the total European EAP population. The
pretreatment status was known from 520 of these patients,
of whom 307 (59%) were chemonaı¨ve and 213 (41%) were
previously treated. Patients in the P arm had a much worse
Karnofsky performance status and had more often received
prior treatment compared with those in the PCb or PC arms.
Although the number of patients with peritoneal mesothe-
lioma was small (nZ 13), it was apparent that they were
relatively young (median 54 years, range 37e66), and those
assigned to treatment with pemetrexedþ cisplatin had
a better performance status (90 or 100 in 6 of 7 patients)sothelioma (safety population) by pretreatment status and
nZ 548) Overall (nZ 548)
Z 137) P* (nZ 191) PCb* (nZ 220)
(38e77) 64 (39e81) 66 (35e85) 65 (35e85)
(91) 158 (83) 185 (84) 467 (85)
(99) 191 (100) 220 (100) 547 (100)
(69) 81 (42) 149 (68) 324 (59)
(30) 107 (56) 67 (30) 215 (39)
(0) 1 (1) 0 (0) 1 (<1)
(1) 2 (1) 4 (2) 8 (1)
(19) 131/187 (70) 58/206 (28) 213/520 (41)
(7) 13 (7) 16 (7) 38 (7)
(66) 132 (69) 159 (72) 382 (70)
(14) 16 (8) 21 (10) 56 (10)
(13) 30 (16) 24 (11) 72 (13)
oplatin.
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pemetrexedþ carboplatin.
Treatment exposure
Overall, patients with pleural mesothelioma received
a median of 5 cycles (range, 1e44) of the study treatment,
with onlyminor differences between the treatment arms (PC:
6 [1e44],P:5 [1e15], PCb:6 [1e34]).Treatmentexposurewas
comparable in the patient group with peritoneal mesothe-
lioma (median 6 cycles, range 2e35). Overall, one or more
dose delays and/or reductions during the course of treatment
were required for pemetrexed, cisplatin, and carboplatin in
35%, 26%, and 45% of the patients, respectively. Relative dose
intensity was approximately 98% for pemetrexed in all treat-
ment arms, and 95% for cisplatin. The most common reasons
for discontinuation of the study included lack of efficacy
(30%), tumor progression (29%), or satisfactory response
(23%). In the monotherapy arm, treatment tended to be dis-
continued more often due to progressive disease compared
with PCb and PC (38% vs. 28% vs. 19%).
Safety
Hematologic toxicity observed in the patient group with
pleural mesothelioma is shown in Table 2. The incidence of
grade 3/4 anemia and leukopenia was similar among
treatment arms, while grade 3/4 neutropenia and throm-
bocytopenia was less common in the pemetrexed arm.
Only 3 patients (0.5%) died of adverse events probably or
possibly related to study therapy (2 in the P arm with neu-
tropenic sepsis and 1 in the PCb arm with pancytopenia).
Efficacy
Treatment outcome is summarized in Table 3. Twelve
patients with peritoneal and 498 patients with pleural
mesothelioma were evaluable for response. In the patient
group with pleural mesothelioma, there were 3 complete
and 90 partial responses, resulting in an overall responseTable 2 Hematologic toxicity among patients with pleural mes
PC* (nZ 137) P* (nZ 191)
Anemia
na 134 186
Grade 3/4, n (%) 21 (16) 37 (20)
Leukopenia
na 134 186
Grade 3/4, n (%) 30 (22) 28 (15)
Neutropenia
na 130 180
Grade 3/4, n (%) 37 (29) 28 (16)
Thrombopenia
na 134 186
Grade 3/4, n (%) 17 (13) 12 (7)
*PC, pemetrexedþ cisplatin; P, pemetrexed; PCb, pemetrexedþ carb
**c2 test.
a Designates the total number of patients with available data for arate of 19%. In addition, 280 patients (56%) had stable
disease. The highest response rate was achieved in the PC
arm (24% [95% CI 17e32%] vs. 16% [95% CI 10e22%] in the P
arm vs. 18% [95% CI 13e24%] in the PCb arm), but the
difference between the groups was not was not significant.
Response was comparable between chemonaı¨ve patients
(20%, 95% CI 15e25%) and previously treated patients (16%,
95% CI 11e22%). Only one (8%) out of 12 evaluable patients
with peritoneal mesothelioma achieved a partial response,
but 8 (67%) had stable disease.
Median TTP among evaluable patients with pleural
mesothelioma was 6.9 months (95% CI 6.2e7.8) in the total
population. The longest TTP was achieved in the PC arm,
with a median of 8.2 months (95% CI 7.0e8.6) compared
with 5.5 months (95% CI 4.9e7.2) in the P arm and 6.9
months (95% CI 5.8e7.6) in the PCb arm; the difference
between groups was significant in the log-rank test
(pZ 0.004). Median TTP was 7.6 months (95% CI 6.7e8.3)
for chemonaı¨ve patients compared with 5.6 months (95% CI
4.9e6.9) for previously treated patients.
Median OS was 10.1 months (95% CI 8.6e11.6) for all
patientswith pleuralmesothelioma, and 11.3months (95% CI
7.7 to undetermined) in the PC arm, 8.7months (95% CI 7.0 to
undetermined) in theParm,and9.7months (7.1e10.9) in the
PCb arm (Figure 1). The difference in OS between arms was
not significant (log-rank pZ 0.606), but the percentage of
censored patients was high in all arms (overall, 78%; range,
77% to 80%). Survival at 1 yearwas estimated tobe37% (95%CI
24e49%) in the total population, and 42% (95% CI 24e59%) in
the PC arm, 42% (95% CI 21e62%) in the P arm, and 18%
(0e47%) in the PCb arm. Median OS was 11.6 months (95% CI
9.2 to undetermined) for chemonaı¨ve patients and 8.6
months (6.6e20.4) for previously treated patients with
pleural mesothelioma. Survival of patients with peritoneal
mesothelioma seemed to be longer; results for this subgroup
of patients have been presented in part elsewhere.17
Discussion
This report summarizes the results from 561 patients with
MM who were treated in German centers as part of anothelioma (safety population) by treatment group.
PCb* (nZ 220) Overall (nZ 548) p**
216 536
43 (20) 101 (19) 0.556
216 536
47 (22) 105 (20) 0.154
212 522
78 (37) 143 (27) <0.001
216 536
37 (17) 66 (12) 0.005
oplatin.
specific toxicity.
Table 3 Response and survival by pretreatment status and treatment group in patients with pleural mesothelioma (safety
population).
Chemonaı¨ve
(nZ 282)
Previously treated
(nZ 190)
Total (nZ 498)
PC* (nZ 130) P* (nZ 161) PCb* (nZ 207) Overall (nZ 498)
ORR (CRþ PR),
% [95% CI]
20 [15e25] 16 [11e22] 24 [17e32] 16 [10e22] 18 [13e24] 19 [15e22]
DCR (CRþ PRþ SD),
% [95% CI]
81 [75e85] 69 [62e75] 80 [72e87] 66 [58e73] 79 [73e84] 75 [71e79]
Median TTP, months
[95% CI]
7.6 [6.7e8.3] 5.6 [4.9e6.9] 8.2 [7.0e8.6] 5.5 [4.9e7.2] 6.9 [5.8e7.6] 6.9 [6.2e7.8]
Median OS, months
[95% CI]
11.6 [9.2eud] 8.6 [6.6e20.4] 11.3 [7.7eud] 8.7 [7.0eud] 9.7 [7.1e10.9] 10.1 [8.6e11.6]
1-year survival,
% [95% CI]
47 [27e66] 38 [22e54] 42 [24e59] 42 [21e62] 18 [0e47] 37 [24e49]
*PC, pemetrexedþ cisplatin; P, pemetrexed; PCb, pemetrexedþ carboplatin.
95% CI, 95% confidence interval; CR, complete response; DCR, disease control rate; ORR, overall response rate; OS, overall survival;
PR, partial response; SD, stable disease; TTP, time to progression; ud, undetermined.
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or without a platinum agent. All but 13 patients had pleural
mesothelioma. Thus, the patient population with pleural
mesothelioma constituted the basis of this report. It was
shown that all treatment regimens were feasible in routine
clinical practice and well tolerated, although patients
receiving pemetrexed alone experienced the mildest
hematologic toxicity. The difference in TTP between groups
was statistically significant and clinically meaningful, with
the longest median TTP seen among patients treated with
PC (8.2 months). However, this did not translate into
a statistically significant difference in overall survival
between the treatment groups.
There are some limitations of this trial that are related
to the study design and warrant caution in interpreting the
results. This study was an Expanded Access Program,
therefore there was no control arm. The patients were not
randomly assigned to the different treatment arms. Rather,
it was left to the discretion of the investigators which
chemotherapy regimen they applied, taking into account
the clinical status of the individual patient and the intent of
therapy. In addition, the high proportion of censored
patients limits the accuracy of the survival estimates.
Irrespective of these limitations, the study findings clearly
demonstrated a favorable safety profile for all chemo-
therapy options with pemetrexed. Dose intensity of
chemotherapy could be maintained as planned in the
majority of patients, and only 3 patients (0.5%) died of
adverse events probably or possibly related to study
therapy.
The differences in baseline characteristics seen among
patients of the three treatment groups might reflect the
process of clinical decision-making. Single agent treatment
with pemetrexed was the preferred choice for previously
treated patients with a poor performance status, while
most patients treated with pemetrexed/cisplatin or
pemetrexed/carboplatin were chemonaı¨ve and physically
fit. Despite these important differences at baseline, there
was a remarkable similarity between the groups with regard
to treatment exposure and outcome measures.Objective response rates were in the range of 20%, but
another 50e60% of the patients had disease stabilization.
Thus, between 66% (pemetrexed alone) and 80% (peme-
trexed/cisplatin) of thepatients benefited fromtreatment in
terms of disease control. The good clinical response was also
reflected by a median TTP of 5.5 and 8.2 months, and
a median OS of 8.7 and 11.3 months for single agent peme-
trexed andpemetrexed/cisplatin, respectively.Outcome for
patients treated with pemetrexed/carboplatin was inter-
mediate between the other two groups, but 95% confidence
intervals for all outcome measures were overlapping
between the treatment groups, and a comparison of the
three survival curves using a long-rank test did not show
a significant difference. Remarkably,median overall survival
of previously treated patients (62% of whom received single
agent pemetrexed) was 8.6 months for all treatment groups
combined, suggesting good activity of pemetrexed-based
second-line therapy. Unfortunately, the type of pretreat-
ment was not available from the EAP database.
This report is one of a series of recently published EAP
reports that described clinical experience with pemetrexed
alone or in combination with a platinum agent in malignant
mesothelioma. The non-US international EAP, part of which
was the German population described herein, has already
reported results for all chemonaı¨ve patients with pleural
mesothelioma receiving treatment with single agent
pemetrexed13 or a pemetrexed-platinum combination.14
The US EAP differed from the international trial in that only
two treatment options were available, either pemetrexed
alone or pemetrexed plus cisplatin. The efficacy data from
this program indicated that the combination of pemetrexed
with a platinum was more effective in terms of higher
response and disease control rates and longer median
survival, both in chemonaı¨ve and previously treated
patients, compared with single agent pemetrexed.18e20
These data are consistent with our observations suggesting
a superiority of PC compared with monotherapy. In che-
monaı¨ve patients, the difference in survival between the
combination and single agent pemetrexed was significant
(10.9 vs. 4.8 months, PZ 0.001).19 Although baseline
Figure 1 Kaplan-Meier plot of survival time by treatment arm in pleural mesothelioma population in Germany (evaluable
population). MTAZ pemetrexed.
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publication, it is reasonable to assume that similar to our
population, patients treated with single agent pemetrexed
were more likely to be in a poorer clinical condition than
those offered the platinum combination, thus putting the
survival difference into perspective.
While combination chemotherapy with pemetrexed and
cisplatin has been established as standard first-line therapy
for MM, based on the phase III results reported by Vogelzang
et al.,12 there is accumulating evidence that previously
treated patients may also benefit from treatment with
pemetrexed. The objective response rate of 16% and the
disease control rate (CRþ PRþ SD) of 69% seen in our study
with second-line pemetrexed therapy are in keeping with
this concept, and the survival seen in this study, with
a median OS of 8.6 months (37 weeks) and a 1-year survival
of 38%, indicates second-line treatment offers a clinically
meaningful benefit.
A randomized controlled study compared pemetrexed
with best supportive care as second-line therapy in 243
patients with pleural mesothelioma.21 Response rate with
pemetrexed was 19%, and median TTP was significantly
improved compared with BSC (3.7 vs. 1.5 months;
PZ 0.0002), but median OS was similar in both groups.
Sørensen et al.22 reported on 39 patients who were previ-
ously treated with platinum-based chemotherapy without
pemetrexed. Second-line therapy consisted of single agent
pemetrexed in 28 patients and pemetrexed/carboplatin in
11 patients. Both regimens were similarly effective.
Response rate was approximately 20%, median TTP 21
weeks with pemetrexed and 32 weeks with the combina-
tion, and median OS approximately 40 weeks for both
regimens. Bogaert et al. 23 explored the possibility of
pemetrexed maintenance therapy after successful induc-
tion with a pemetrexed-based regimen. They found that
stable disease was converted to a partial response in 3 of 13patients receiving maintenance treatment with peme-
trexed with or without carboplatin, and progression-free
and overall survival in the maintenance group was signifi-
cantly longer compared with the 14 patients who did not
receive maintenance therapy (median TTP, 8.5 vs. 3.4
months; median OS, 17.9 vs. 6.0 months; P< 0.0001 for
both comparisons).
In conclusion, our results obtained in the German
patient population of an international expanded access
program are largely consistent with the experience in other
EAPs and clinical studies of malignant mesothelioma. It was
shown that pemetrexed given alone or in combination with
cisplatin or carboplatin is safe and effective as first and
second-line therapy in pleural mesothelioma. In particular,
single agent pemetrexed could be a valuable treatment
option for pretreated patients which may offer substantial
clinical benefit. Preliminary evidence suggests that peme-
trexed-based chemotherapy has similar activity in perito-
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